Chemours (CC) Misses Q4 EPS by 2c, Beats on Revenue; Offers Guidance

Chemours (NYSE: CC) reported Q4 EPS of $0.05, $0.02 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.

Key Full Year 2026 Outlook5

Consolidated Net Sales growth in the range of 3 to 5%
Adjusted EBITDA between $800 million and $900 million
Free Cash Flow Conversion above 25%

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters
• JPMorgan Starts Central Depository Services India Ltd (CDSL:IN) at Underweight